Commonwealth legislation

National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4) (PB 41 of 2017)

RepealedCTH

This Act has been repealed and is no longer in force. It is retained for historical reference.

Jurisdiction

Commonwealth

Collection

legislative instrument

Plain English Summary

2/10 complexity

This determination updates the lists of subsidised medicines under the Pharmaceutical Benefits Scheme (PBS). The PBS divides medicines into two baskets: F1 (single-brand medicines, usually still under patent) and F2 (multi-brand or generic medicines with multiple suppliers).

What it does:

Removes five medicines from the single-brand list (F1): Colestipol, Etanercept, Fluphenazine Decanoate, Rosiglitazone, and plain Fluticasone
Moves two medicines to the multi-brand list (F2): Fluticasone and Zonisamide — this happens when generic alternatives become available
Adds a new combination inhaler to F1: Fluticasone furoate with vilanterol
Adds Fluticasone and Fluticasone with Salmeterol to F2

Why it matters: When medicines shift to F2, competition between manufacturers usually drives down prices. This changes what patients pay as a co-payment and how much the government subsidises.

JSON API Health / NDIS / medicines

Deep dive

Want the full deep dive?

Zoe can write the in-depth analysis on top of the summary above: how it works, who it affects and what each part actually does.

Current sections

Direct links to the current provisions in National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4) (PB 41 of 2017).

National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4) (PB 41 of 2017)

View image in the official source

PB 41 of 2017

National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4)

National Health Act 1953

I, LOUISE CLARKE, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated 30 May 2017

LOUISE CLARKE

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

Part 1 Preliminary

1 Name of Determination

(1) This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4).

(2) This Determination may also be cited as PB 41 of 2017.

2 Commencement

This Determination commences on 1 June 2017.

3 Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1 Amendments

(Section 3)

[1] Schedule 1, after item dealing with Codeine

Omit

Colestipol

[2] Schedule 1, after item dealing with Essential amino acids formula with vitamins and minerals

Omit

Etanercept

[3] Schedule 1, after item dealing with Flupenthixol Decanoate

Omit

Fluphenazine Decanoate

Fluticasone

Insert

Fluticasone furoate with vilanterol

[4] Schedule 1, after item dealing with Romiplostim

Omit

Rosiglitazone

[5] Schedule 1, after item dealing with Zidovudine

Omit

Zonisamide

[6] Schedule 2, after item dealing with Flutamide

Insert

Fluticasone

Fluticasone with Salmeterol

[7] Schedule 2, after item dealing with Zolmitriptan

Insert

Zonisamide

Source text

Sourced from the Federal Register of Legislation (legislation.gov.au), CC BY 4.0.

1 National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4) (PB 41 of 2017)

PB 41 of 2017

National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4)

National Health Act 1953

Dated 30 May 2017

LOUISE CLARKE

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

Part 1 Preliminary

1 Name of Determination

(1) This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4).

(2) This Determination may also be cited as PB 41 of 2017.

2 Commencement

This Determination commences on 1 June 2017.

3 Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1 Amendments

(Section 3)

[1] Schedule 1, after item dealing with Codeine

Omit

Colestipol

[2] Schedule 1, after item dealing with Essential amino acids formula with vitamins and minerals

Omit

Etanercept

[3] Schedule 1, after item dealing with Flupenthixol Decanoate

Omit

Fluphenazine Decanoate

Fluticasone

Insert

Fluticasone furoate with vilanterol

[4] Schedule 1, after item dealing with Romiplostim

Omit

Rosiglitazone

[5] Schedule 1, after item dealing with Zidovudine

Omit

Zonisamide

[6] Schedule 2, after item dealing with Flutamide

Insert

Fluticasone

Fluticasone with Salmeterol

[7] Schedule 2, after item dealing with Zolmitriptan

Insert

Zonisamide